MD2 inhibition reduced retinal damage after I/R induction in mice. TBHP induced TLR4/MD2 binding via increasing HMGB-1 expression. TLR4/MD2 initiated inflammatory response via activation of MAPKs and NF-κB. MD2 could be the therapeutic target for the treatment of retinal I/R.